Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zhihao Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8368-5129; OpenAlex author ID A5102002640. Sources: OpenAlex.

Their work

Papers
2
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2024: 1 paper · 2025: none · 2026: 1 paper

Papers 2

  1. Nicotinamide riboside enhances the efficacy of gemcitabine and suppresses PDAC premalignant lesions via SIRT3 activation. Co-author DOI 10.1016/j.bcp.2025.117585↗
  2. Pancreatic STAT5 activation promotes Kras G12D-induced and inflammation-induced acinar-to-ductal metaplasia and pancreatic cancer. Co-author DOI 10.1136/gutjnl-2024-332225↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yuli Lin · 2 shared papers, 2024–2026 · strength 0.49
  2. Xuguang Yang · 1 shared paper, 2026 · strength 0.30
  3. Xiangjun Meng · 1 shared paper, 2024 · strength 0.18
  4. Jun Wang · 1 shared paper, 2024 · strength 0.18
  5. Qing Xia · 1 shared paper, 2024 · strength 0.18
  6. Wenquan Wang · 1 shared paper, 2024 · strength 0.18
  7. Liang Liu · 1 shared paper, 2024 · strength 0.18
  8. Xuguang Yang · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.